S'abonner

Home NIV treatment quality in patients with chronic respiratory failure having participated to the French nationwide telemonitoring experimental program (The TELVENT study) - 15/09/23

Doi : 10.1016/j.resmer.2023.101028 
Sandrine Pontier-Marchandise a, , Joelle Texereau b, c, Arnaud Prigent d, Jésus Gonzalez-Bermejo e, f, Claudio Rabec g, Frédéric Gagnadoux h, Alexia Letierce i, Joao Carlos Winck j
a Department of Respiratory Medicine, Larrey Hospital, Toulouse University Hospital, Toulouse, France 
b Lung Function & Respiratory Physiology Units, Cochin University Hospital, AP-HP, Paris, France 
c VitalAire, Air Liquide Healthcare, Bagneux, France 
d Pulmonology Medical Group, Polyclinique Saint-Laurent, Rennes, France 
e Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, F-75005, Paris, France 
f AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, SSR respiratoire (Département R3S), F-75013, Paris, France 
g Pulmonary Department and Respiratory Critical Care Unit, Dijon University Hospital, Dijon, France 
h Department of Respiratory and Sleep Medicine, Angers University hospital and INSERM 1083, UMR CNRS 6015, MITOVASC, Equipe CarME, SFR ICAT, University of Angers, 49000 Angers, France 
i QualityStat – Morangis, France 
j Faculdade de Medicina da Universidade do Porto, Porto, Portugal 

Corresponding author at: Department of Respiratory Medicine, Larrey Hospital, CHU Toulouse, 24 chemin de Pouvourville, 31059 Toulouse, France.Department of Respiratory MedicineLarrey Hospital, CHU Toulouse24 chemin de PouvourvilleToulouse31059France

Abstract

Background

The ETAPES program is a national telemedicine experiment conducted in France between 2018 and 2023 to investigate whether home non-invasive ventilation (NIV) telemonitoring improves healthcare pathways in patients with chronic respiratory failure (CRF) and impacts healthcare organization. The program provides a combination of therapeutic education and NIV telemonitoring with data processed by an algorithm generating alerts. The TELVENT study objective was to analyze the evolution of ventilation quality in patients included in the ETAPES program.

Methods

Multicentric cohort study on patients undergoing long-term NIV included in the ETAPES program between September 2018 and December 2020 and who did not refuse the use of their data for this research. Data were obtained from homecare provider databases. The primary endpoint was to attain successful NIV treatment, which was determined by a combination of daily NIV usage for > 4 h per day, low leaks, and a low apnea-hypopnea index (AHI) identified by the NIV device. Respiratory disability was assessed using the DIRECT questionnaire.

Results

329 patients were included in the study of which 145 had COPD and 83 had started NIV and ETAPES within one-month delay. Approximately 25% of patients did not achieve the criteria for successful NIV at ETAPES entry. The proportion of patients with successful NIV treatment increased to 86.8% at six months (p = 0.003, Cochran-Armitage trend test) regardless of NIV history and continued to increase at 12 months in newly equipped NIV patients (93.8%, at month 12, p = 0.0026 for trend test). Over time, a significant increase in NIV use and compliance was observed, while AHI significantly decreased in the overall population. No significant decrease was observed for non-intentional leaks. Approximately 4.9 alerts were generated per patient per 6 months. Their number and type (low NIV use, high AHI or leaks) differed among patients based on their NIV history. Respiratory disability score decreased over time compared with baseline.

Conclusion

The TELVENT study highlights the importance of remote NIV monitoring to rapidly identify patients with unsuccessful ventilation. The combination of remote monitoring and therapeutic education may improve the quality of home NIV, especially in the first months of treatment.

Le texte complet de cet article est disponible en PDF.

Keywords : ETAPES, Telemonitoring, NIV, Chronic respiratory failure


Plan


© 2023  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 84

Article 101028- novembre 2023 Retour au numéro
Article précédent Article précédent
  • Recovery of Endothelium-dependent vascular relaxation impairment in convalescent COVID-19 patients: Insight from a pilot study
  • Fares Gouzi, Aurélien Philippe, Jean Pastre, Bertrand Renaud, Nicolas Gendron, Marielle Subileau, Thông Hua-Huy, Benjamin Planquette, Olivier Sanchez, David M. Smadja, Sven Günther
| Article suivant Article suivant
  • Eosinophil recovery in hospitalized COVID-19 patients is associated with lower rates of ICU admission and in-hospital mortality: An observational cohort analysis
  • Peter D. Yan, Daniela Markovic, Roxana Y. Hixson, Carolyn M. Shover, Russell G. Buhr, Ramin Salehi-Rad, Blake LeMaster, Donald P. Tashkin, Jennifer A. Fulcher, Igor Z. Barjaktarevic

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.